These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8453001)

  • 21. How NICE may be outflanked.
    Ferner RE; McDowell SE
    BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342
    [No Abstract]   [Full Text] [Related]  

  • 22. Should NICE's threshold range for cost per QALY be raised? Yes.
    Towse A
    BMJ; 2009 Jan; 338():b181. PubMed ID: 19171561
    [No Abstract]   [Full Text] [Related]  

  • 23. Value-based pricing of drugs in the UK.
    Webb DJ; Walker A
    Lancet; 2007 Apr; 369(9571):1415-1416. PubMed ID: 17467498
    [No Abstract]   [Full Text] [Related]  

  • 24. Patent office backlog adds billions to national drug expenditure.
    Gaudry KS; Cummings DE
    Nat Biotechnol; 2014 May; 32(5):436-9. PubMed ID: 24811513
    [No Abstract]   [Full Text] [Related]  

  • 25. Getting new drugs to market: how individuals could do this without leaving their desks.
    Collier J
    BMJ; 2006 Dec; 333(7582):1315-7. PubMed ID: 17185722
    [No Abstract]   [Full Text] [Related]  

  • 26. [Scientific concept of providing Russian population with drugs].
    Nechaev EA
    Vestn Ross Akad Med Nauk; 1994; (7):5-10. PubMed ID: 7524855
    [No Abstract]   [Full Text] [Related]  

  • 27. [The need for joint evaluation of pharmaceutical expenditure and the health outcomes obtained].
    Soto Álvarez J
    Gac Sanit; 2011; 25(3):257. PubMed ID: 21459490
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacy management strategies for responding to hospital reimbursement changes.
    Curtiss FR
    Am J Hosp Pharm; 1983 Sep; 40(9):1489-92. PubMed ID: 6353913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limited options to manage specialty drug spending.
    Tu HT; Samuel DR
    Res Brief; 2012 Apr; (22):1-13. PubMed ID: 23155549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can ICER bring cost-effectiveness to drug prices?
    Butcher L
    Manag Care; 2019 Jun; 28(6):30-33. PubMed ID: 31188097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Link cost to clinical outcome.
    Norris J
    BMJ; 2007 May; 334(7601):968. PubMed ID: 17493992
    [No Abstract]   [Full Text] [Related]  

  • 33. Assessment of the opportunities for pharmaceutical manufacturers in emerging markets.
    Anderson T; Olson J; Sobelman D
    J Manag Care Pharm; 2009 Jun; 15(5):396-402. PubMed ID: 19496636
    [No Abstract]   [Full Text] [Related]  

  • 34. [Germany's Novartis Chief proposes "More competition through decentralized contracts"].
    Kosche D; Färber L
    MMW Fortschr Med; 2010 Aug; 152(31-33):6-7. PubMed ID: 20828056
    [No Abstract]   [Full Text] [Related]  

  • 35. Economic consequences of unused medications in Houston, Texas.
    Garey KW; Johle ML; Behrman K; Neuhauser MM
    Ann Pharmacother; 2004; 38(7-8):1165-8. PubMed ID: 15138296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value for money of drug regulation.
    Bouvy JC; Koopmanschap MA; Schellekens H
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):247-9. PubMed ID: 22812545
    [No Abstract]   [Full Text] [Related]  

  • 37. [Follow up studies as a condition for drug subsidizing].
    Kieler H; Ekbom A; Fored M; Montgomery SM; Wettermark B
    Lakartidningen; 2009 May 13-19; 106(20):1406-7. PubMed ID: 19585842
    [No Abstract]   [Full Text] [Related]  

  • 38. The relative value of disease management programs versus drug manufacturer rebates.
    Curtiss FR
    J Manag Care Pharm; 2003; 9(6):573-4. PubMed ID: 14664669
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug industry is considering more use of differential pricing, conference hears.
    Sukkar E
    BMJ; 2011 Dec; 343():d8049. PubMed ID: 22155726
    [No Abstract]   [Full Text] [Related]  

  • 40. Pricing schemes for new drugs: a welfare analysis.
    Levaggi R
    Soc Sci Med; 2014 Feb; 102():69-73. PubMed ID: 24565143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.